Global Ataxia Market
Global Ataxia Market

Ataxia Comprehensive Study by Type (Cerebellar Ataxia, Sensory Ataxia, Vestibular Ataxia), Treatment (Adaptive Devices, Therapies (Physical Therapy, Occupational Therapy and Speech Therapy), Medications), End-users (Hospitals, Clinics, Others), Diagnosis (CT scan or MRI, Lumbar Puncture, Genetic Testing), Symptoms (Lack of coordination, Slurred speech, Trouble eating and swallowing, Deterioration of fine motor skills, Difficulty walking, Gait abnormalities, Eye movement abnormalities, Tremors, Heart problems) Players and Region - Global Market Outlook to 2025

Ataxia Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 230 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Ataxia Market?

Ataxia is a degenerative disease of the nervous system that involves a lack of muscle control or coordination of voluntary movements, such as walking or picking up objects. This condition affects a personís speech, eye movements, and ability to swallow, walk, and pick up objects, among other voluntary movements. This condition in some people is due to genetic factors and in some people can result due to another condition, such as a stroke, MS, a brain tumor, or a head injury, or even from excessive alcohol consumption.

The market study is being classified by Type (Cerebellar Ataxia, Sensory Ataxia and Vestibular Ataxia) and major geographies with country level break-up.

Pfizer, Inc. (United States), Acorda Therapeutics, Inc. (United States), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Forest Laboratories (United States), H. Lundbeck A/S (Denmark), Johnson & Johnson (United States), Merck & Co., Inc. (United States) and Sanofi S.A. (France) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Ataxia market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Ataxia market by Type, Application and Region.

On the basis of geography, the market of Ataxia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Diagnosis Rate of Ataxia due Rise in Number of Diagnostic Centres and Hospitals
  • Increasing Awareness about Ataxia among People

Market Trend
  • Technological Advancements in Medical Science
  • Increased Research and Development Activities

Restraints
  • No Single Product Approval for Ataxia Treatment

Opportunities
  • Growing Demand for Proper Cure for Ataxia
  • Growth in the Healthcare Industry Worldwide

Challenges
  • Recent Expiry of Certain Drugs that Treat Symptomatic Ataxia


In July 2019, REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, has announced it entered into a license agreement with Pfizer Inc.


Key Target Audience
Ataxia Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Cerebellar Ataxia
  • Sensory Ataxia
  • Vestibular Ataxia
By Treatment
  • Adaptive Devices
  • Therapies (Physical Therapy, Occupational Therapy and Speech Therapy)
  • Medications

By End-users
  • Hospitals
  • Clinics
  • Others

By Diagnosis
  • CT scan or MRI
  • Lumbar Puncture
  • Genetic Testing

By Symptoms
  • Lack of coordination
  • Slurred speech
  • Trouble eating and swallowing
  • Deterioration of fine motor skills
  • Difficulty walking
  • Gait abnormalities
  • Eye movement abnormalities
  • Tremors
  • Heart problems

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Diagnosis Rate of Ataxia due Rise in Number of Diagnostic Centres and Hospitals
      • 3.2.2. Increasing Awareness about Ataxia among People
    • 3.3. Market Challenges
      • 3.3.1. Recent Expiry of Certain Drugs that Treat Symptomatic Ataxia
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Medical Science
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ataxia, by Type, Treatment, End-users, Diagnosis, Symptoms and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Ataxia (Value)
      • 5.2.1. Global Ataxia by: Type (Value)
        • 5.2.1.1. Cerebellar Ataxia
        • 5.2.1.2. Sensory Ataxia
        • 5.2.1.3. Vestibular Ataxia
      • 5.2.2. Global Ataxia by: Treatment (Value)
        • 5.2.2.1. Adaptive Devices
        • 5.2.2.2. Therapies (Physical Therapy, Occupational Therapy and Speech Therapy)
        • 5.2.2.3. Medications
      • 5.2.3. Global Ataxia by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Ataxia by: Diagnosis (Value)
        • 5.2.4.1. CT scan or MRI
        • 5.2.4.2. Lumbar Puncture
        • 5.2.4.3. Genetic Testing
      • 5.2.5. Global Ataxia by: Symptoms (Value)
        • 5.2.5.1. Lack of coordination
        • 5.2.5.2. Slurred speech
        • 5.2.5.3. Trouble eating and swallowing
        • 5.2.5.4. Deterioration of fine motor skills
        • 5.2.5.5. Difficulty walking
        • 5.2.5.6. Gait abnormalities
        • 5.2.5.7. Eye movement abnormalities
        • 5.2.5.8. Tremors
        • 5.2.5.9. Heart problems
      • 5.2.6. Global Ataxia Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Ataxia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Acorda Therapeutics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Forest Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. H. Lundbeck A/S (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ataxia Sale, by Type, Treatment, End-users, Diagnosis, Symptoms and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Ataxia (Value)
      • 7.2.1. Global Ataxia by: Type (Value)
        • 7.2.1.1. Cerebellar Ataxia
        • 7.2.1.2. Sensory Ataxia
        • 7.2.1.3. Vestibular Ataxia
      • 7.2.2. Global Ataxia by: Treatment (Value)
        • 7.2.2.1. Adaptive Devices
        • 7.2.2.2. Therapies (Physical Therapy, Occupational Therapy and Speech Therapy)
        • 7.2.2.3. Medications
      • 7.2.3. Global Ataxia by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Ataxia by: Diagnosis (Value)
        • 7.2.4.1. CT scan or MRI
        • 7.2.4.2. Lumbar Puncture
        • 7.2.4.3. Genetic Testing
      • 7.2.5. Global Ataxia by: Symptoms (Value)
        • 7.2.5.1. Lack of coordination
        • 7.2.5.2. Slurred speech
        • 7.2.5.3. Trouble eating and swallowing
        • 7.2.5.4. Deterioration of fine motor skills
        • 7.2.5.5. Difficulty walking
        • 7.2.5.6. Gait abnormalities
        • 7.2.5.7. Eye movement abnormalities
        • 7.2.5.8. Tremors
        • 7.2.5.9. Heart problems
      • 7.2.6. Global Ataxia Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ataxia: by Type(USD Million)
  • Table 2. Ataxia Cerebellar Ataxia , by Region USD Million (2014-2019)
  • Table 3. Ataxia Sensory Ataxia , by Region USD Million (2014-2019)
  • Table 4. Ataxia Vestibular Ataxia , by Region USD Million (2014-2019)
  • Table 5. Ataxia: by Treatment(USD Million)
  • Table 6. Ataxia Adaptive Devices , by Region USD Million (2014-2019)
  • Table 7. Ataxia Therapies (Physical Therapy, Occupational Therapy and Speech Therapy) , by Region USD Million (2014-2019)
  • Table 8. Ataxia Medications , by Region USD Million (2014-2019)
  • Table 9. Ataxia: by End-users(USD Million)
  • Table 10. Ataxia Hospitals , by Region USD Million (2014-2019)
  • Table 11. Ataxia Clinics , by Region USD Million (2014-2019)
  • Table 12. Ataxia Others , by Region USD Million (2014-2019)
  • Table 13. Ataxia: by Diagnosis(USD Million)
  • Table 14. Ataxia CT scan or MRI , by Region USD Million (2014-2019)
  • Table 15. Ataxia Lumbar Puncture , by Region USD Million (2014-2019)
  • Table 16. Ataxia Genetic Testing , by Region USD Million (2014-2019)
  • Table 17. Ataxia: by Symptoms(USD Million)
  • Table 18. Ataxia Lack of coordination , by Region USD Million (2014-2019)
  • Table 19. Ataxia Slurred speech , by Region USD Million (2014-2019)
  • Table 20. Ataxia Trouble eating and swallowing , by Region USD Million (2014-2019)
  • Table 21. Ataxia Deterioration of fine motor skills , by Region USD Million (2014-2019)
  • Table 22. Ataxia Difficulty walking , by Region USD Million (2014-2019)
  • Table 23. Ataxia Gait abnormalities , by Region USD Million (2014-2019)
  • Table 24. Ataxia Eye movement abnormalities , by Region USD Million (2014-2019)
  • Table 25. Ataxia Tremors , by Region USD Million (2014-2019)
  • Table 26. Ataxia Heart problems , by Region USD Million (2014-2019)
  • Table 27. South America Ataxia, by Country USD Million (2014-2019)
  • Table 28. South America Ataxia, by Type USD Million (2014-2019)
  • Table 29. South America Ataxia, by Treatment USD Million (2014-2019)
  • Table 30. South America Ataxia, by End-users USD Million (2014-2019)
  • Table 31. South America Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 32. South America Ataxia, by Symptoms USD Million (2014-2019)
  • Table 33. Brazil Ataxia, by Type USD Million (2014-2019)
  • Table 34. Brazil Ataxia, by Treatment USD Million (2014-2019)
  • Table 35. Brazil Ataxia, by End-users USD Million (2014-2019)
  • Table 36. Brazil Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 37. Brazil Ataxia, by Symptoms USD Million (2014-2019)
  • Table 38. Argentina Ataxia, by Type USD Million (2014-2019)
  • Table 39. Argentina Ataxia, by Treatment USD Million (2014-2019)
  • Table 40. Argentina Ataxia, by End-users USD Million (2014-2019)
  • Table 41. Argentina Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 42. Argentina Ataxia, by Symptoms USD Million (2014-2019)
  • Table 43. Rest of South America Ataxia, by Type USD Million (2014-2019)
  • Table 44. Rest of South America Ataxia, by Treatment USD Million (2014-2019)
  • Table 45. Rest of South America Ataxia, by End-users USD Million (2014-2019)
  • Table 46. Rest of South America Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 47. Rest of South America Ataxia, by Symptoms USD Million (2014-2019)
  • Table 48. Asia Pacific Ataxia, by Country USD Million (2014-2019)
  • Table 49. Asia Pacific Ataxia, by Type USD Million (2014-2019)
  • Table 50. Asia Pacific Ataxia, by Treatment USD Million (2014-2019)
  • Table 51. Asia Pacific Ataxia, by End-users USD Million (2014-2019)
  • Table 52. Asia Pacific Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 53. Asia Pacific Ataxia, by Symptoms USD Million (2014-2019)
  • Table 54. China Ataxia, by Type USD Million (2014-2019)
  • Table 55. China Ataxia, by Treatment USD Million (2014-2019)
  • Table 56. China Ataxia, by End-users USD Million (2014-2019)
  • Table 57. China Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 58. China Ataxia, by Symptoms USD Million (2014-2019)
  • Table 59. Japan Ataxia, by Type USD Million (2014-2019)
  • Table 60. Japan Ataxia, by Treatment USD Million (2014-2019)
  • Table 61. Japan Ataxia, by End-users USD Million (2014-2019)
  • Table 62. Japan Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 63. Japan Ataxia, by Symptoms USD Million (2014-2019)
  • Table 64. India Ataxia, by Type USD Million (2014-2019)
  • Table 65. India Ataxia, by Treatment USD Million (2014-2019)
  • Table 66. India Ataxia, by End-users USD Million (2014-2019)
  • Table 67. India Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 68. India Ataxia, by Symptoms USD Million (2014-2019)
  • Table 69. South Korea Ataxia, by Type USD Million (2014-2019)
  • Table 70. South Korea Ataxia, by Treatment USD Million (2014-2019)
  • Table 71. South Korea Ataxia, by End-users USD Million (2014-2019)
  • Table 72. South Korea Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 73. South Korea Ataxia, by Symptoms USD Million (2014-2019)
  • Table 74. Taiwan Ataxia, by Type USD Million (2014-2019)
  • Table 75. Taiwan Ataxia, by Treatment USD Million (2014-2019)
  • Table 76. Taiwan Ataxia, by End-users USD Million (2014-2019)
  • Table 77. Taiwan Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 78. Taiwan Ataxia, by Symptoms USD Million (2014-2019)
  • Table 79. Australia Ataxia, by Type USD Million (2014-2019)
  • Table 80. Australia Ataxia, by Treatment USD Million (2014-2019)
  • Table 81. Australia Ataxia, by End-users USD Million (2014-2019)
  • Table 82. Australia Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 83. Australia Ataxia, by Symptoms USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Ataxia, by Type USD Million (2014-2019)
  • Table 85. Rest of Asia-Pacific Ataxia, by Treatment USD Million (2014-2019)
  • Table 86. Rest of Asia-Pacific Ataxia, by End-users USD Million (2014-2019)
  • Table 87. Rest of Asia-Pacific Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 88. Rest of Asia-Pacific Ataxia, by Symptoms USD Million (2014-2019)
  • Table 89. Europe Ataxia, by Country USD Million (2014-2019)
  • Table 90. Europe Ataxia, by Type USD Million (2014-2019)
  • Table 91. Europe Ataxia, by Treatment USD Million (2014-2019)
  • Table 92. Europe Ataxia, by End-users USD Million (2014-2019)
  • Table 93. Europe Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 94. Europe Ataxia, by Symptoms USD Million (2014-2019)
  • Table 95. Germany Ataxia, by Type USD Million (2014-2019)
  • Table 96. Germany Ataxia, by Treatment USD Million (2014-2019)
  • Table 97. Germany Ataxia, by End-users USD Million (2014-2019)
  • Table 98. Germany Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 99. Germany Ataxia, by Symptoms USD Million (2014-2019)
  • Table 100. France Ataxia, by Type USD Million (2014-2019)
  • Table 101. France Ataxia, by Treatment USD Million (2014-2019)
  • Table 102. France Ataxia, by End-users USD Million (2014-2019)
  • Table 103. France Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 104. France Ataxia, by Symptoms USD Million (2014-2019)
  • Table 105. Italy Ataxia, by Type USD Million (2014-2019)
  • Table 106. Italy Ataxia, by Treatment USD Million (2014-2019)
  • Table 107. Italy Ataxia, by End-users USD Million (2014-2019)
  • Table 108. Italy Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 109. Italy Ataxia, by Symptoms USD Million (2014-2019)
  • Table 110. United Kingdom Ataxia, by Type USD Million (2014-2019)
  • Table 111. United Kingdom Ataxia, by Treatment USD Million (2014-2019)
  • Table 112. United Kingdom Ataxia, by End-users USD Million (2014-2019)
  • Table 113. United Kingdom Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 114. United Kingdom Ataxia, by Symptoms USD Million (2014-2019)
  • Table 115. Netherlands Ataxia, by Type USD Million (2014-2019)
  • Table 116. Netherlands Ataxia, by Treatment USD Million (2014-2019)
  • Table 117. Netherlands Ataxia, by End-users USD Million (2014-2019)
  • Table 118. Netherlands Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 119. Netherlands Ataxia, by Symptoms USD Million (2014-2019)
  • Table 120. Rest of Europe Ataxia, by Type USD Million (2014-2019)
  • Table 121. Rest of Europe Ataxia, by Treatment USD Million (2014-2019)
  • Table 122. Rest of Europe Ataxia, by End-users USD Million (2014-2019)
  • Table 123. Rest of Europe Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 124. Rest of Europe Ataxia, by Symptoms USD Million (2014-2019)
  • Table 125. MEA Ataxia, by Country USD Million (2014-2019)
  • Table 126. MEA Ataxia, by Type USD Million (2014-2019)
  • Table 127. MEA Ataxia, by Treatment USD Million (2014-2019)
  • Table 128. MEA Ataxia, by End-users USD Million (2014-2019)
  • Table 129. MEA Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 130. MEA Ataxia, by Symptoms USD Million (2014-2019)
  • Table 131. Middle East Ataxia, by Type USD Million (2014-2019)
  • Table 132. Middle East Ataxia, by Treatment USD Million (2014-2019)
  • Table 133. Middle East Ataxia, by End-users USD Million (2014-2019)
  • Table 134. Middle East Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 135. Middle East Ataxia, by Symptoms USD Million (2014-2019)
  • Table 136. Africa Ataxia, by Type USD Million (2014-2019)
  • Table 137. Africa Ataxia, by Treatment USD Million (2014-2019)
  • Table 138. Africa Ataxia, by End-users USD Million (2014-2019)
  • Table 139. Africa Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 140. Africa Ataxia, by Symptoms USD Million (2014-2019)
  • Table 141. North America Ataxia, by Country USD Million (2014-2019)
  • Table 142. North America Ataxia, by Type USD Million (2014-2019)
  • Table 143. North America Ataxia, by Treatment USD Million (2014-2019)
  • Table 144. North America Ataxia, by End-users USD Million (2014-2019)
  • Table 145. North America Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 146. North America Ataxia, by Symptoms USD Million (2014-2019)
  • Table 147. United States Ataxia, by Type USD Million (2014-2019)
  • Table 148. United States Ataxia, by Treatment USD Million (2014-2019)
  • Table 149. United States Ataxia, by End-users USD Million (2014-2019)
  • Table 150. United States Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 151. United States Ataxia, by Symptoms USD Million (2014-2019)
  • Table 152. Canada Ataxia, by Type USD Million (2014-2019)
  • Table 153. Canada Ataxia, by Treatment USD Million (2014-2019)
  • Table 154. Canada Ataxia, by End-users USD Million (2014-2019)
  • Table 155. Canada Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 156. Canada Ataxia, by Symptoms USD Million (2014-2019)
  • Table 157. Mexico Ataxia, by Type USD Million (2014-2019)
  • Table 158. Mexico Ataxia, by Treatment USD Million (2014-2019)
  • Table 159. Mexico Ataxia, by End-users USD Million (2014-2019)
  • Table 160. Mexico Ataxia, by Diagnosis USD Million (2014-2019)
  • Table 161. Mexico Ataxia, by Symptoms USD Million (2014-2019)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Ataxia: by Type(USD Million)
  • Table 173. Ataxia Cerebellar Ataxia , by Region USD Million (2020-2025)
  • Table 174. Ataxia Sensory Ataxia , by Region USD Million (2020-2025)
  • Table 175. Ataxia Vestibular Ataxia , by Region USD Million (2020-2025)
  • Table 176. Ataxia: by Treatment(USD Million)
  • Table 177. Ataxia Adaptive Devices , by Region USD Million (2020-2025)
  • Table 178. Ataxia Therapies (Physical Therapy, Occupational Therapy and Speech Therapy) , by Region USD Million (2020-2025)
  • Table 179. Ataxia Medications , by Region USD Million (2020-2025)
  • Table 180. Ataxia: by End-users(USD Million)
  • Table 181. Ataxia Hospitals , by Region USD Million (2020-2025)
  • Table 182. Ataxia Clinics , by Region USD Million (2020-2025)
  • Table 183. Ataxia Others , by Region USD Million (2020-2025)
  • Table 184. Ataxia: by Diagnosis(USD Million)
  • Table 185. Ataxia CT scan or MRI , by Region USD Million (2020-2025)
  • Table 186. Ataxia Lumbar Puncture , by Region USD Million (2020-2025)
  • Table 187. Ataxia Genetic Testing , by Region USD Million (2020-2025)
  • Table 188. Ataxia: by Symptoms(USD Million)
  • Table 189. Ataxia Lack of coordination , by Region USD Million (2020-2025)
  • Table 190. Ataxia Slurred speech , by Region USD Million (2020-2025)
  • Table 191. Ataxia Trouble eating and swallowing , by Region USD Million (2020-2025)
  • Table 192. Ataxia Deterioration of fine motor skills , by Region USD Million (2020-2025)
  • Table 193. Ataxia Difficulty walking , by Region USD Million (2020-2025)
  • Table 194. Ataxia Gait abnormalities , by Region USD Million (2020-2025)
  • Table 195. Ataxia Eye movement abnormalities , by Region USD Million (2020-2025)
  • Table 196. Ataxia Tremors , by Region USD Million (2020-2025)
  • Table 197. Ataxia Heart problems , by Region USD Million (2020-2025)
  • Table 198. South America Ataxia, by Country USD Million (2020-2025)
  • Table 199. South America Ataxia, by Type USD Million (2020-2025)
  • Table 200. South America Ataxia, by Treatment USD Million (2020-2025)
  • Table 201. South America Ataxia, by End-users USD Million (2020-2025)
  • Table 202. South America Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 203. South America Ataxia, by Symptoms USD Million (2020-2025)
  • Table 204. Brazil Ataxia, by Type USD Million (2020-2025)
  • Table 205. Brazil Ataxia, by Treatment USD Million (2020-2025)
  • Table 206. Brazil Ataxia, by End-users USD Million (2020-2025)
  • Table 207. Brazil Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 208. Brazil Ataxia, by Symptoms USD Million (2020-2025)
  • Table 209. Argentina Ataxia, by Type USD Million (2020-2025)
  • Table 210. Argentina Ataxia, by Treatment USD Million (2020-2025)
  • Table 211. Argentina Ataxia, by End-users USD Million (2020-2025)
  • Table 212. Argentina Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 213. Argentina Ataxia, by Symptoms USD Million (2020-2025)
  • Table 214. Rest of South America Ataxia, by Type USD Million (2020-2025)
  • Table 215. Rest of South America Ataxia, by Treatment USD Million (2020-2025)
  • Table 216. Rest of South America Ataxia, by End-users USD Million (2020-2025)
  • Table 217. Rest of South America Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 218. Rest of South America Ataxia, by Symptoms USD Million (2020-2025)
  • Table 219. Asia Pacific Ataxia, by Country USD Million (2020-2025)
  • Table 220. Asia Pacific Ataxia, by Type USD Million (2020-2025)
  • Table 221. Asia Pacific Ataxia, by Treatment USD Million (2020-2025)
  • Table 222. Asia Pacific Ataxia, by End-users USD Million (2020-2025)
  • Table 223. Asia Pacific Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 224. Asia Pacific Ataxia, by Symptoms USD Million (2020-2025)
  • Table 225. China Ataxia, by Type USD Million (2020-2025)
  • Table 226. China Ataxia, by Treatment USD Million (2020-2025)
  • Table 227. China Ataxia, by End-users USD Million (2020-2025)
  • Table 228. China Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 229. China Ataxia, by Symptoms USD Million (2020-2025)
  • Table 230. Japan Ataxia, by Type USD Million (2020-2025)
  • Table 231. Japan Ataxia, by Treatment USD Million (2020-2025)
  • Table 232. Japan Ataxia, by End-users USD Million (2020-2025)
  • Table 233. Japan Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 234. Japan Ataxia, by Symptoms USD Million (2020-2025)
  • Table 235. India Ataxia, by Type USD Million (2020-2025)
  • Table 236. India Ataxia, by Treatment USD Million (2020-2025)
  • Table 237. India Ataxia, by End-users USD Million (2020-2025)
  • Table 238. India Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 239. India Ataxia, by Symptoms USD Million (2020-2025)
  • Table 240. South Korea Ataxia, by Type USD Million (2020-2025)
  • Table 241. South Korea Ataxia, by Treatment USD Million (2020-2025)
  • Table 242. South Korea Ataxia, by End-users USD Million (2020-2025)
  • Table 243. South Korea Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 244. South Korea Ataxia, by Symptoms USD Million (2020-2025)
  • Table 245. Taiwan Ataxia, by Type USD Million (2020-2025)
  • Table 246. Taiwan Ataxia, by Treatment USD Million (2020-2025)
  • Table 247. Taiwan Ataxia, by End-users USD Million (2020-2025)
  • Table 248. Taiwan Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 249. Taiwan Ataxia, by Symptoms USD Million (2020-2025)
  • Table 250. Australia Ataxia, by Type USD Million (2020-2025)
  • Table 251. Australia Ataxia, by Treatment USD Million (2020-2025)
  • Table 252. Australia Ataxia, by End-users USD Million (2020-2025)
  • Table 253. Australia Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 254. Australia Ataxia, by Symptoms USD Million (2020-2025)
  • Table 255. Rest of Asia-Pacific Ataxia, by Type USD Million (2020-2025)
  • Table 256. Rest of Asia-Pacific Ataxia, by Treatment USD Million (2020-2025)
  • Table 257. Rest of Asia-Pacific Ataxia, by End-users USD Million (2020-2025)
  • Table 258. Rest of Asia-Pacific Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 259. Rest of Asia-Pacific Ataxia, by Symptoms USD Million (2020-2025)
  • Table 260. Europe Ataxia, by Country USD Million (2020-2025)
  • Table 261. Europe Ataxia, by Type USD Million (2020-2025)
  • Table 262. Europe Ataxia, by Treatment USD Million (2020-2025)
  • Table 263. Europe Ataxia, by End-users USD Million (2020-2025)
  • Table 264. Europe Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 265. Europe Ataxia, by Symptoms USD Million (2020-2025)
  • Table 266. Germany Ataxia, by Type USD Million (2020-2025)
  • Table 267. Germany Ataxia, by Treatment USD Million (2020-2025)
  • Table 268. Germany Ataxia, by End-users USD Million (2020-2025)
  • Table 269. Germany Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 270. Germany Ataxia, by Symptoms USD Million (2020-2025)
  • Table 271. France Ataxia, by Type USD Million (2020-2025)
  • Table 272. France Ataxia, by Treatment USD Million (2020-2025)
  • Table 273. France Ataxia, by End-users USD Million (2020-2025)
  • Table 274. France Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 275. France Ataxia, by Symptoms USD Million (2020-2025)
  • Table 276. Italy Ataxia, by Type USD Million (2020-2025)
  • Table 277. Italy Ataxia, by Treatment USD Million (2020-2025)
  • Table 278. Italy Ataxia, by End-users USD Million (2020-2025)
  • Table 279. Italy Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 280. Italy Ataxia, by Symptoms USD Million (2020-2025)
  • Table 281. United Kingdom Ataxia, by Type USD Million (2020-2025)
  • Table 282. United Kingdom Ataxia, by Treatment USD Million (2020-2025)
  • Table 283. United Kingdom Ataxia, by End-users USD Million (2020-2025)
  • Table 284. United Kingdom Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 285. United Kingdom Ataxia, by Symptoms USD Million (2020-2025)
  • Table 286. Netherlands Ataxia, by Type USD Million (2020-2025)
  • Table 287. Netherlands Ataxia, by Treatment USD Million (2020-2025)
  • Table 288. Netherlands Ataxia, by End-users USD Million (2020-2025)
  • Table 289. Netherlands Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 290. Netherlands Ataxia, by Symptoms USD Million (2020-2025)
  • Table 291. Rest of Europe Ataxia, by Type USD Million (2020-2025)
  • Table 292. Rest of Europe Ataxia, by Treatment USD Million (2020-2025)
  • Table 293. Rest of Europe Ataxia, by End-users USD Million (2020-2025)
  • Table 294. Rest of Europe Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 295. Rest of Europe Ataxia, by Symptoms USD Million (2020-2025)
  • Table 296. MEA Ataxia, by Country USD Million (2020-2025)
  • Table 297. MEA Ataxia, by Type USD Million (2020-2025)
  • Table 298. MEA Ataxia, by Treatment USD Million (2020-2025)
  • Table 299. MEA Ataxia, by End-users USD Million (2020-2025)
  • Table 300. MEA Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 301. MEA Ataxia, by Symptoms USD Million (2020-2025)
  • Table 302. Middle East Ataxia, by Type USD Million (2020-2025)
  • Table 303. Middle East Ataxia, by Treatment USD Million (2020-2025)
  • Table 304. Middle East Ataxia, by End-users USD Million (2020-2025)
  • Table 305. Middle East Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 306. Middle East Ataxia, by Symptoms USD Million (2020-2025)
  • Table 307. Africa Ataxia, by Type USD Million (2020-2025)
  • Table 308. Africa Ataxia, by Treatment USD Million (2020-2025)
  • Table 309. Africa Ataxia, by End-users USD Million (2020-2025)
  • Table 310. Africa Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 311. Africa Ataxia, by Symptoms USD Million (2020-2025)
  • Table 312. North America Ataxia, by Country USD Million (2020-2025)
  • Table 313. North America Ataxia, by Type USD Million (2020-2025)
  • Table 314. North America Ataxia, by Treatment USD Million (2020-2025)
  • Table 315. North America Ataxia, by End-users USD Million (2020-2025)
  • Table 316. North America Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 317. North America Ataxia, by Symptoms USD Million (2020-2025)
  • Table 318. United States Ataxia, by Type USD Million (2020-2025)
  • Table 319. United States Ataxia, by Treatment USD Million (2020-2025)
  • Table 320. United States Ataxia, by End-users USD Million (2020-2025)
  • Table 321. United States Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 322. United States Ataxia, by Symptoms USD Million (2020-2025)
  • Table 323. Canada Ataxia, by Type USD Million (2020-2025)
  • Table 324. Canada Ataxia, by Treatment USD Million (2020-2025)
  • Table 325. Canada Ataxia, by End-users USD Million (2020-2025)
  • Table 326. Canada Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 327. Canada Ataxia, by Symptoms USD Million (2020-2025)
  • Table 328. Mexico Ataxia, by Type USD Million (2020-2025)
  • Table 329. Mexico Ataxia, by Treatment USD Million (2020-2025)
  • Table 330. Mexico Ataxia, by End-users USD Million (2020-2025)
  • Table 331. Mexico Ataxia, by Diagnosis USD Million (2020-2025)
  • Table 332. Mexico Ataxia, by Symptoms USD Million (2020-2025)
  • Table 333. Research Programs/Design for This Report
  • Table 334. Key Data Information from Secondary Sources
  • Table 335. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ataxia: by Type USD Million (2014-2019)
  • Figure 5. Global Ataxia: by Treatment USD Million (2014-2019)
  • Figure 6. Global Ataxia: by End-users USD Million (2014-2019)
  • Figure 7. Global Ataxia: by Diagnosis USD Million (2014-2019)
  • Figure 8. Global Ataxia: by Symptoms USD Million (2014-2019)
  • Figure 9. South America Ataxia Share (%), by Country
  • Figure 10. Asia Pacific Ataxia Share (%), by Country
  • Figure 11. Europe Ataxia Share (%), by Country
  • Figure 12. MEA Ataxia Share (%), by Country
  • Figure 13. North America Ataxia Share (%), by Country
  • Figure 14. Global Ataxia share by Players 2019 (%)
  • Figure 15. Global Ataxia share by Players (Top 3) 2019(%)
  • Figure 16. Global Ataxia share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer, Inc. (United States) Revenue: by Geography 2019
  • Figure 20. Acorda Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Acorda Therapeutics, Inc. (United States) Revenue: by Geography 2019
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue: by Geography 2019
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2019
  • Figure 26. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 28. Forest Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 29. Forest Laboratories (United States) Revenue: by Geography 2019
  • Figure 30. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. H. Lundbeck A/S (Denmark) Revenue: by Geography 2019
  • Figure 32. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 34. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 36. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 37. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 38. Global Ataxia: by Type USD Million (2020-2025)
  • Figure 39. Global Ataxia: by Treatment USD Million (2020-2025)
  • Figure 40. Global Ataxia: by End-users USD Million (2020-2025)
  • Figure 41. Global Ataxia: by Diagnosis USD Million (2020-2025)
  • Figure 42. Global Ataxia: by Symptoms USD Million (2020-2025)
  • Figure 43. South America Ataxia Share (%), by Country
  • Figure 44. Asia Pacific Ataxia Share (%), by Country
  • Figure 45. Europe Ataxia Share (%), by Country
  • Figure 46. MEA Ataxia Share (%), by Country
  • Figure 47. North America Ataxia Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer, Inc. (United States)
  • Acorda Therapeutics, Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Eli Lilly and Company (United States)
  • Forest Laboratories (United States)
  • H. Lundbeck A/S (Denmark)
  • Johnson & Johnson (United States)
  • Merck & Co., Inc. (United States)
  • Sanofi S.A. (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation